An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones

BACKGROUND: DAV132 (colon-targeted adsorbent) has prevented antibiotic-induced effects on microbiota in healthy volunteers. OBJECTIVES: To assess DAV132 safety and biological efficacy in patients. PATIENTS AND METHODS: An open-label, randomized [stratification: fluoroquinolone (FQ) indication] multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vehreschild, Maria J. G. T., Ducher, Annie, Louie, Thomas, Cornely, Oliver A., Feger, Celine, Dane, Aaron, Varastet, Marina, Vitry, Fabien, de Gunzburg, Jean, Andremont, Antoine, Mentré, France, Wilcox, Mark H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969469/
https://www.ncbi.nlm.nih.gov/pubmed/35016205
http://dx.doi.org/10.1093/jac/dkab474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969469/
https://www.ncbi.nlm.nih.gov/pubmed/35016205
http://dx.doi.org/10.1093/jac/dkab474

Ejemplares similares